TMCnet News
US and Europe Insulin Market 2016-2020 - Advances in Insulin Delivery Technology Drives the Market - Research and MarketsResearch and Markets has announced the addition of the "Insulin Market in the US and Europe 2016-2020" report to their offering. The insulin market in the US and Europe to grow at a CAGR of 6.17% during the period 2016-2020 The report covers the present scenario and the growth prospects of the insulin market in the US and Europe for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period. The report also includes a discussion of the key vendors operating in this market. A trend to note is the rising prices of insulin drugs. Apart from safety and efficacy, the cost of therapy plays a major role in deciding the number of consumers. The cost-effectiveness of a treatment needs to be analyzed while prescribing a therapy. However, due to the lack of alternative therapies, drugs like insulin are the standard treatment options despite their high cost. The insulin market in the US and Europe is expected to grow based on the rising prices of insulin analogs. According to the report, a key growth driver is the advances in insulin delivery technology. The development of innovative insulin products and advances in insulin delivery technology have increased the life expectancy of individuals with diabetes. Automated injection devices such as insulin pumps and pens offers a safe and easy drug delivery option, increasing their demand in the market. For instance, NovoPen and FlexTouch by Novo Nordisk are the latest developments in durable insulin delivery devices. Further, the report states that one challenge that could have an adverse impact on market growth is the complexity of the insulin production process. Key vendors - Sanofi - Novo Nordisk - Eli Lilly Other prominent vendors - Adocia - Biocon - Biodel - Biogenomics
- Dance Biopharm - Diasome Pharmaceuticals - Exsulin - Generex - Lexicon Pharmaceuticals - Ligand Pharmaceuticals - MannKind - Macrogenics - Merck - Melior Pharmaceuticals - Metabolic Solutions Development Company - NGM Biopharmaceuticals - NuSirt Biopharma - Oramed Pharmceuticals - PhaseBio Pharmaceuticals - Pfizer - Thermalin Diabetes - Tolerion - VeroScience - vTv Therapeutics - Wockhardt - XOMA Key Topics Covered: PART 01: Executive summary - Highlights PART 02: Scope of the report - Market overview - Assumptions - Top-vendor offerings PART 03: Market research methodology - Research methodology - Economic indicators PART 04: Introduction - Key market highlights - Key buying criteria PART 05: Major branded drug profiles - Actrapid - Apidra - Humalog - Insuman - Lantus - Levemir - NovoMix - NovoRapid - Toujeo - Tresiba PART 06: Insulin: An overview - History of insulin - Epidemiology - Reimbursement scenario - Patent scenario for approved products PART 07: Pipeline portfolio - Xultophy (NN9068) - Faster-acting insulin as PART (NN1218) - SAR342434 - LY2605541 - MK-1293 - Oral-Lyn PART 08: Oral insulin therapies - Upcoming vendors for oral insulin therapies - Oramed Pharmaceuticals - Generex Biotechnology PART 09: Market landscape - Global insulin market - Insulin market in US and Europe - Market size and forecast - Five forces analysis PART 10: Market segmentation by drug class - Fast-acting insulin - Intermediate-acting insulin - Long-acting insulin PART 11: Market segmentation by application - Type 1 diabetes - Type 2 diabetes PART 12: Market segmentation by insulin delivery technologies - Injectable insulin - Oral insulin - Inhaled insulin - Other emerging insulin delivery technologies - Insulin pumps PART 13: Geographical segmentation - Insulin market in US - Insulin market in Europe PART 14: Market drivers - Advances in insulin delivery technology - Unmet medical needs - Increase in prevalence of diabetes and obesity - Increase in awareness of diabetes PART 15: Impact of drivers PART 16: Market challenges - Complexity of insulin production - Poor storage condition and distribution policies - Stringent regulatory environment - Inconvenient ROA PART 17: Impact of drivers and challenges PART 18: Market trends - Increase in R&D for novel mechanisms - Increase in academia-industry collaborations for drug development - Increasing price of insulin drugs - Intense competition among present and upcoming vendors PART 19: Vendor landscape For more information visit http://www.researchandmarkets.com/research/qnmtsw/insulin_market_in
View source version on businesswire.com: http://www.businesswire.com/news/home/20160524005895/en/ |